Galapagos Earns EUR 2mn Partial Milestone From Servier

Galapagos has received EUR 2mn for a partial milestone in its osteoarthritis (OA) alliance with Servier. This payment contributes to Group revenues in 2013.

In July 2010, Servier and Galapagos announced their alliance to develop new oral medicines for the treatment of OA. Galapagos is responsible for the discovery and development of new candidate drugs against novel targets, and Servier has an exclusive option to licence these after the completion of Phase I trials. Galapagos is eligible to receive up to EUR 290mn in success-based milestones, plus royalties on commercial sales. Galapagos also retains exclusive US commercialisation rights to all commercial compounds.

Pharma Agreement Database
Companies Involved Galapagos, Servier
Date Announced 07/03/2014
Agreement Status Updated
Date Last Reported 06/03/2013
Agreement Type Commercialisation, Development, Research
Estimated Total Value >EUR 290mn
Investment To Date
Therapeutic Area Anti-inflammatory, Antineoplastic and Immunomodulating Agents
Technology/Field Drug Development, Drug Discovery
Related Agreement Galapagos achieves milestone in Servier OA/oncology alliance
Source: Espicom.
This article is tagged to:
Related sectors of this article: Pharmaceuticals & Healthcare, Musculoskeletal, Agreements - Pharmaceuticals
Geography: Belgium, France

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.